SK16022003A3 - Tricyklické dihydrochinolínové zlúčeniny, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú - Google Patents

Tricyklické dihydrochinolínové zlúčeniny, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú Download PDF

Info

Publication number: SK16022003A3
Authority: SK; Slovakia
Prior art keywords: straight; group; branched; formula; alkyl
Prior art date: 2001-05-23

Application number

SK1602-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Henri-Philippe Husson

Sylviane Giorgi-Renault

St�Phanie Desbene

John Hickman

Alain Pierre

Laurence Kraus-Berthier

Bruno Pfeiffer

Pierre Renard

Original Assignee

Les Laboratoires Servier

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-23

Filing date

2002-05-22

Publication date

2004-05-04

2002-05-22 Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier

2004-05-04 Publication of SK16022003A3 publication Critical patent/SK16022003A3/sk

Links

238000000034 method Methods 0.000 title claims description 9
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
150000001875 compounds Chemical class 0.000 claims abstract description 84
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 36
125000003118 aryl group Chemical group 0.000 claims description 28
229910052757 nitrogen Inorganic materials 0.000 claims description 28
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
125000000217 alkyl group Chemical group 0.000 claims description 21
125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 19
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 15
125000001072 heteroaryl group Chemical group 0.000 claims description 15
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
230000003287 optical effect Effects 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
125000005842 heteroatom Chemical group 0.000 claims description 11
229910052760 oxygen Inorganic materials 0.000 claims description 11
229910052717 sulfur Inorganic materials 0.000 claims description 11
150000004677 hydrates Chemical class 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
239000012453 solvate Substances 0.000 claims description 10
150000007513 acids Chemical class 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
125000002950 monocyclic group Chemical group 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
-1 biphenylyl Chemical group 0.000 claims description 8
125000003277 amino group Chemical group 0.000 claims description 7
125000004429 atom Chemical group 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 7
125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
125000002619 bicyclic group Chemical group 0.000 claims description 5
125000000623 heterocyclic group Chemical group 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
125000004434 sulfur atom Chemical group 0.000 claims description 5
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
125000004122 cyclic group Chemical group 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
125000002252 acyl group Chemical group 0.000 claims description 3
125000005530 alkylenedioxy group Chemical group 0.000 claims description 3
239000002246 antineoplastic agent Substances 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
238000000746 purification Methods 0.000 claims description 2
229920006395 saturated elastomer Polymers 0.000 claims description 2
238000000926 separation method Methods 0.000 claims description 2
239000011593 sulfur Chemical group 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
229940041181 antineoplastic drug Drugs 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000000259 anti-tumor effect Effects 0.000 abstract description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 10
210000004027 cell Anatomy 0.000 description 7
239000000203 mixture Substances 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
239000007858 starting material Substances 0.000 description 6
XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 5
238000010992 reflux Methods 0.000 description 5
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 4
239000003814 drug Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
PEQJBOMPGWYIRO-UHFFFAOYSA-N n-ethyl-3,4-dimethoxyaniline Chemical compound CCNC1=CC=C(OC)C(OC)=C1 PEQJBOMPGWYIRO-UHFFFAOYSA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
238000004452 microanalysis Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
241001061127 Thione Species 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000001816 cooling Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
125000005044 dihydroquinolinyl group Chemical class N1(CC=CC2=CC=CC=C12)* 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
OFVNZOJVKWKSPT-UHFFFAOYSA-N n-benzyl-1,3-benzodioxol-5-amine Chemical compound C=1C=C2OCOC2=CC=1NCC1=CC=CC=C1 OFVNZOJVKWKSPT-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
MJWDKAHWCMOBIQ-UHFFFAOYSA-N 11-(3,4,5-trimethoxyphenyl)-14-oxa-17-azatetracyclo[8.7.0.02,7.012,16]heptadeca-1(10),2,4,6,8,12(16)-hexaene-13-thione Chemical compound COC1=C(OC)C(OC)=CC(C2C3=C(C4=CC=CC=C4C=C3)NC3=C2C(OC3)=S)=C1 MJWDKAHWCMOBIQ-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
VUGQIIQFXCXZJU-UHFFFAOYSA-N 3,4,5-trimethoxyacetophenone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1OC VUGQIIQFXCXZJU-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
RUXHWBMJNBBYNL-UHFFFAOYSA-N 3-hydroxy-1,2-dihydropyrrol-5-one Chemical compound OC1=CC(=O)NC1 RUXHWBMJNBBYNL-UHFFFAOYSA-N 0.000 description 1
ZFMZSZMUFWRAOG-UHFFFAOYSA-N 3-methoxy-n-methylaniline Chemical compound CNC1=CC=CC(OC)=C1 ZFMZSZMUFWRAOG-UHFFFAOYSA-N 0.000 description 1
MHSHYGPGWOOSQK-UHFFFAOYSA-N 3H-oxathiolo[4,3-b]quinoline Chemical compound S1OCC2=NC=3C=CC=CC=3C=C21 MHSHYGPGWOOSQK-UHFFFAOYSA-N 0.000 description 1
WTCISQGOKRLRTM-UHFFFAOYSA-N 5,5-dimethyloxolane-2,4-dione Chemical compound CC1(C)OC(=O)CC1=O WTCISQGOKRLRTM-UHFFFAOYSA-N 0.000 description 1
FQOUCLOASADFCF-UHFFFAOYSA-N 8-methyl-8-(3,4,5-trimethoxyphenyl)-5,12,14-trioxa-2-azatetracyclo[7.7.0.03,7.011,15]hexadeca-1(16),3(7),9,11(15)-tetraen-6-one Chemical compound COC1=C(OC)C(OC)=CC(C2(C)C3=CC=4OCOC=4C=C3NC3=C2C(OC3)=O)=C1 FQOUCLOASADFCF-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
230000003255 anti-acne Effects 0.000 description 1
230000003262 anti-osteoporosis Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
244000309464 bull Species 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
GETMSPZIIJLCJJ-UHFFFAOYSA-N chembl486110 Chemical compound COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3NC3=C2C(NC3)=O)=C1 GETMSPZIIJLCJJ-UHFFFAOYSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004979 cyclopentylene group Chemical group 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
125000004957 naphthylene group Chemical group 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
DJPYQQRDRWANEP-UHFFFAOYSA-N oxathiolan-4-one Chemical compound O=C1COSC1 DJPYQQRDRWANEP-UHFFFAOYSA-N 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
238000007280 thionation reaction Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SK1602-2003A 2001-05-23 2002-05-22 Tricyklické dihydrochinolínové zlúčeniny, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú SK16022003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0106792A FR2825091B1 (fr)	2001-05-23	2001-05-23	Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2002/001715 WO2002094835A1 (fr)	2001-05-23	2002-05-22	Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
SK16022003A3 true SK16022003A3 (sk)	2004-05-04

Family

ID=8863589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1602-2003A SK16022003A3 (sk)	2001-05-23	2002-05-22	Tricyklické dihydrochinolínové zlúčeniny, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú

Country Status (18)

Country	Link
US (1)	US20040198981A1 (es)
EP (1)	EP1389210A1 (es)
JP (1)	JP2004535405A (es)
KR (1)	KR20030097898A (es)
CN (1)	CN1511158A (es)
AR (1)	AR033915A1 (es)
BR (1)	BR0209974A (es)
CA (1)	CA2448191A1 (es)
CZ (1)	CZ20033495A3 (es)
EA (1)	EA200301171A1 (es)
FR (1)	FR2825091B1 (es)
HU (1)	HUP0400436A2 (es)
MX (1)	MXPA03010599A (es)
NO (1)	NO20035215L (es)
PL (1)	PL364082A1 (es)
SK (1)	SK16022003A3 (es)
WO (1)	WO2002094835A1 (es)
ZA (1)	ZA200308629B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2339676T3 (es) *	2005-07-20	2010-05-24	Aventis Pharma S.A.	Heterociclicos condensados con 1,4-dihidropiridina, procedimiento par a prepararlos, uso y composiciones que los contienen.
US8927560B2 (en)	2010-12-06	2015-01-06	Council Of Scientific & Industrial Research	4-Aza-2, 3-didehydropodophyllotoxin compounds and process for the preparation thereof
CA2936874A1 (en)	2014-01-15	2015-07-23	Guy Chabot	Water soluble 4-azapodophyllotoxin analogs
WO2017151947A1 (en) *	2016-03-02	2017-09-08	George Robert Pettit	4-azapodophylotoxins compounds
CN111494374B (zh) *	2020-06-12	2021-08-03	广东省微生物研究所（广东省微生物分析检测中心）	香草木宁碱在制备破骨细胞分化抑制剂中的应用
CN114989180B (zh) *	2022-05-26	2024-06-04	广东海洋大学	杨叶肖槿内生真菌来源的化合物及其制备方法与应用
KR20250033298A (ko) *	2022-07-12	2025-03-07	오레곤 헬스 앤드 사이언스 유니버시티	아조포도필로톡신 유도체 su056의 거울상이성질체
US11731980B1 (en)	2023-03-22	2023-08-22	King Faisal University	Furo[3,4-b]quinolone compounds as antibacterial agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2801310B1 (fr) *	1999-11-24	2004-04-16	Adir	NOUVEAUX DERIVES DE DIHYDROFURO-[3,4-b]QUINOLEIN-1-ONES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

2001
- 2001-05-23 FR FR0106792A patent/FR2825091B1/fr not_active Expired - Fee Related
2002
- 2002-05-22 PL PL02364082A patent/PL364082A1/xx unknown
- 2002-05-22 CA CA002448191A patent/CA2448191A1/fr not_active Abandoned
- 2002-05-22 EA EA200301171A patent/EA200301171A1/ru unknown
- 2002-05-22 KR KR10-2003-7015306A patent/KR20030097898A/ko not_active Ceased
- 2002-05-22 CN CNA028102746A patent/CN1511158A/zh active Pending
- 2002-05-22 CZ CZ20033495A patent/CZ20033495A3/cs unknown
- 2002-05-22 EP EP02740805A patent/EP1389210A1/fr not_active Withdrawn
- 2002-05-22 SK SK1602-2003A patent/SK16022003A3/sk unknown
- 2002-05-22 HU HU0400436A patent/HUP0400436A2/hu unknown
- 2002-05-22 US US10/477,258 patent/US20040198981A1/en not_active Abandoned
- 2002-05-22 JP JP2002591508A patent/JP2004535405A/ja not_active Withdrawn
- 2002-05-22 BR BR0209974-8A patent/BR0209974A/pt not_active Application Discontinuation
- 2002-05-22 MX MXPA03010599A patent/MXPA03010599A/es unknown
- 2002-05-22 WO PCT/FR2002/001715 patent/WO2002094835A1/fr not_active Ceased
- 2002-05-23 AR ARP020101906A patent/AR033915A1/es not_active Application Discontinuation
2003
- 2003-11-05 ZA ZA200308629A patent/ZA200308629B/en unknown
- 2003-11-24 NO NO20035215A patent/NO20035215L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR0209974A (pt)	2004-04-06
FR2825091A1 (fr)	2002-11-29
FR2825091B1 (fr)	2003-07-04
HUP0400436A2 (hu)	2004-09-28
ZA200308629B (en)	2004-11-05
KR20030097898A (ko)	2003-12-31
AR033915A1 (es)	2004-01-07
WO2002094835A1 (fr)	2002-11-28
US20040198981A1 (en)	2004-10-07
PL364082A1 (en)	2004-12-13
NO20035215D0 (no)	2003-11-24
CA2448191A1 (fr)	2002-11-28
MXPA03010599A (es)	2004-03-09
EP1389210A1 (fr)	2004-02-18
NO20035215L (no)	2003-11-24
JP2004535405A (ja)	2004-11-25
CN1511158A (zh)	2004-07-07
CZ20033495A3 (en)	2004-05-12
EA200301171A1 (ru)	2004-04-29

Publication	Publication Date	Title
WO2004101570A1 (en)	2004-11-25	Sulfur-containing naphthoylimide derivatives
EP0305093B1 (en)	1994-04-06	Imidazo(1,2-b)pyridazine derivatives
Yang et al.	2015	l-Proline catalyzed three-component synthesis of para-naphthoquinone–4-aza-podophyllotoxin hybrids as potent antitumor agents
US6548515B1 (en)	2003-04-15	Dihydrofuro[3,4-b]quinolin-1-one compounds
SK16022003A3 (sk)	2004-05-04	Tricyklické dihydrochinolínové zlúčeniny, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú
US20060079677A1 (en)	2006-04-13	Novel tricyclic azepine derivatives, method for production thereof and pharmaceutical compositions comprising the same
CZ20033496A3 (cs)	2004-04-14	Tricyklické dihydrochinolinové sloučeniny, způsob jejich přípravy a farmaceutické kompozice které je obsahují
JP4308156B2 (ja)	2009-08-05	新規なベンゾ［ｂ］クロメノ−ナフチリジン−７−オン及びピラノ［２′，３′：７，８］キノ［２，３−ｂ］キノキサリン−７−オン化合物、それらの製法並びにそれらを含む医薬組成物
AU781768B2 (en)	2005-06-09	New indenoindolone compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200510323B (en)	2006-12-27	Benzo[B]pyrano[3,2-H]acridin-2-one cinnamate compounds, a process for their preparation and pharmaceutical compositions containing them
HK1089160A1 (zh)	2006-11-24	具有抗肿瘤活性的喜树硷的7-亚氨基衍生物
HK1089160B (en)	2008-10-31	7-imino derivatives of camptothecin having antitumor activity
CN105693739A (zh)	2016-06-22	二氢吡喃并[3,2-i]喜树碱衍生物及其制备方法和药用用途